190 related articles for article (PubMed ID: 37627093)
41. Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung.
Wolin EM
Chest; 2017 May; 151(5):1141-1146. PubMed ID: 27373769
[TBL] [Abstract][Full Text] [Related]
42. Misleading clinical presentation of carcinoid syndrome.
Famerée L; Van Lier C; Borbath I; Yildiz H; Lemaire J; Baeck M
Acta Gastroenterol Belg; 2021; 84(3):501-503. PubMed ID: 34599576
[TBL] [Abstract][Full Text] [Related]
43. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
[TBL] [Abstract][Full Text] [Related]
44. A single-centre experience with octreotide in the treatment of different hypersecretory syndromes in patients with functional gastroenteropancreatic neuroendocrine tumors.
Berković MC; Altabas V; Herman D; Hrabar D; Goldoni V; Vizner B; Zjacić-Rotkvić V
Coll Antropol; 2007 Jun; 31(2):531-4. PubMed ID: 17847934
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of Clinical Prognostic Factors and Further Delineation of the Effect of Mesenteric Fibrosis on Survival in Advanced Midgut Neuroendocrine Tumours.
Laskaratos FM; Walker M; Wilkins D; Tuck A; Ramakrishnan S; Phillips E; Gertner J; Megapanou M; Papantoniou D; Shah R; Banks J; Vlachou E; Garcia-Hernandez J; Woodbridge L; Papadopoulou A; Grant L; Theocharidou E; Watkins J; Luong TV; Mandair D; Caplin M; Toumpanakis C
Neuroendocrinology; 2018; 107(3):292-304. PubMed ID: 30153671
[TBL] [Abstract][Full Text] [Related]
46. 5-HIAA excretion is not associated with bone metabolism in carcinoid syndrome patients.
van Dijk SC; de Herder WW; Kwekkeboom DJ; Zillikens MC; Feelders RA; van Schaik RH; van Driel M; van Leeuwen JP
Bone; 2012 Jun; 50(6):1260-5. PubMed ID: 22425693
[TBL] [Abstract][Full Text] [Related]
47. Usefulness of chromogranin A, neuron-specific enolase and 5-hydroxyindolacetic acid measurements in patients with malignant carcinoids.
Manfé AZ; Norberto L; Marchesini M; Lumachi F
In Vivo; 2011; 25(6):1027-9. PubMed ID: 22021701
[TBL] [Abstract][Full Text] [Related]
48. Neuroendocrine tumours of the small bowel: interpretation of raised circulating chromogranin A, urinary 5 hydroxy indole acetic acid and circulating neurokinin A.
Ardill JE; Armstrong L; Smye M; Doherty R; McCance DR; Johnston BT
QJM; 2016 Feb; 109(2):111-5. PubMed ID: 25979268
[TBL] [Abstract][Full Text] [Related]
49. Echocardiography in functional midgut neuroendocrine tumors: When and how often.
Castillo JG; Naib T; Zacks JS; Adams DH
Rev Endocr Metab Disord; 2017 Dec; 18(4):411-421. PubMed ID: 29080935
[TBL] [Abstract][Full Text] [Related]
50. The skin as a window to the gut: A case of carcinoid syndrome.
Costa CA; Lopes T; Rodrigues AP; Lamas NJ; Cruz C
Clin Case Rep; 2024 Mar; 12(3):e8641. PubMed ID: 38455854
[TBL] [Abstract][Full Text] [Related]
51. Late-stage diagnosis of carcinoid heart disease due to lack of access to health care.
Sharma A; Fierro ME; Pak S; Thallapureddy K; Awobajo M; Hui D; Otchere P
Cardiooncology; 2023 Jun; 9(1):28. PubMed ID: 37277819
[TBL] [Abstract][Full Text] [Related]
52. Measurement of urinary 5-HIAA: correlation between spot versus 24-h urine collection.
Calanchini M; Tadman M; Krogh J; Fabbri A; Grossman A; Shine B
Endocr Connect; 2019 Aug; 8(8):1082-1088. PubMed ID: 31265996
[TBL] [Abstract][Full Text] [Related]
53. Surgery and Perioperative Management in Small Intestinal Neuroendocrine Tumors.
Deguelte S; Perrier M; Hammoutene C; Cadiot G; Kianmanesh R
J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32708330
[TBL] [Abstract][Full Text] [Related]
54. Diagnosis and Management of Gastrointestinal Neuroendocrine Tumors: A Comprehensive Literature Review.
Yazdanpanah O; Surapaneni S; Shanah L; Kabashneh S
Cureus; 2021 Mar; 13(3):e14006. PubMed ID: 33884247
[TBL] [Abstract][Full Text] [Related]
55. [The diagnostic significance of biochemical markers.].
Lyubimova NV; Kushlinskii NE; Toms MG; Churikova MG; Khariditi TY
Klin Lab Diagn; 2016; 61(7):397-401. PubMed ID: 31529917
[TBL] [Abstract][Full Text] [Related]
56. Activin A in carcinoid heart disease: a possible role in diagnosis and pathogenesis.
Bergestuen DS; Edvardsen T; Aakhus S; Ueland T; Oie E; Vatn M; Aukrust P; Thiis-Evensen E
Neuroendocrinology; 2010; 92(3):168-77. PubMed ID: 20720391
[TBL] [Abstract][Full Text] [Related]
57. Carcinoid Syndrome: Preclinical Models and Future Therapeutic Strategies.
Vitale G; Carra S; Alessi Y; Campolo F; Pandozzi C; Zanata I; Colao A; Faggiano A; On Behalf Of The Nike Group
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835022
[TBL] [Abstract][Full Text] [Related]
58. Incidence and prognosis of patients with small intestinal neuroendocrine tumors in a population based nationwide study.
Snorradottir S; Asgeirsdottir A; Rögnvaldsson S; Jonasson JG; Björnsson ES
Cancer Epidemiol; 2022 Aug; 79():102197. PubMed ID: 35716441
[TBL] [Abstract][Full Text] [Related]
59. Discriminating capacity of indole markers in the diagnosis of carcinoid tumors.
Meijer WG; Kema IP; Volmer M; Willemse PH; de Vries EG
Clin Chem; 2000 Oct; 46(10):1588-96. PubMed ID: 11017936
[TBL] [Abstract][Full Text] [Related]
60. Outcome of carcinoid heart syndrome in patients enrolled in the SwissNet cohort.
Grundmann E; Curioni-Fontecedro A; Christ E; Siebenhüner AR
BMC Cancer; 2023 Apr; 23(1):338. PubMed ID: 37055717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
